## THE LANCET

Volume 362, Number 9385 • Founded 1823 • Published weekly • Saturday August 30, 2003

**EDITORIAL** 

673	Nanomedicine: grounds for optimism, and a call for papers	
	COMMENTARY	
674 W	Liver donation: donor safety comes first O S Surman, M Hertl	70
675	Stem-cell homing and tissue regeneration in ischaemic cardiomyopathy  W-M Franz and others	7:
676	Simple deliverable therapy needed for childhood leukaemia  J Lilleyman	
677	Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?  J Crown	7:
678	Health and development  J P Ruger	7:
	ARTICLES	
679	Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy  The Antiretroviral Therapy (ART) Cohort Collaboration	7:
687 <b>W</b>	Operative morbidity of living liver donors in Japan K Umeshita and others	
691	The effect of a severe disaster on the mental health of adolescents S A Reijneveld and others	7:

## Talking Point

## Living liver donors

'By contrast with western countries, no perioperative mortality was recorded in living liver donors in Japan'

www.thelancet.com

Since the first successful living donor liver transplantation was done in Japan in 1994, the yearly number of operations has risen, reaching 417 in 2001. Little is known, however, about the morbidity and mortality of such donors. Japanese researchers, Koji Umeshita and colleagues, assessed 1841 living liver donors. No perioperative mortality was recorded, but postoperative complications were identified in just over 10% of donors. Donors of the right liver lobe had more complications and a longer postoperative hospital stay than did donors of the left lobe or lateral segment. The authors state that since some donors developed serious complications, morbidity should be reduced to maintain the zero mortality rate. In a Commentary, Owen Surman and Martin Hertl caution that donor safety should override benefit for the recipient.